Raloxifene Evista

Action

Raloxifene, a benzothiophene compound, is a selective estrogen receptor modulator. It has estrogen agonist activity on bone and antagonist activity on breast and uterine tissue. Its anti-osteoporotic effects are probably a consequence of inhibition of osteoclast activity.

Metabolism

Sixty percent of ingested drug is absorbed. It is glucuronidated on first pass in the liver and excreted almost entirely in the feces. Its half-life is about 27 hours. Adverse Reactions

Hot flashes and leg cramps occur. As with other estrogens, there is an increased risk for venous thromboembolism. Caution

Men and premenopausal women are not candidates for raloxifene therapy. The drug is contraindicated in patients with histories of thromboembolic disease and in patients with known hypersensitivity to the drug or components of the tablets. Cholestyramine causes a 60% reduction in absorption and should not be administered together with raloxifene. Risks for breast and gynecologic malignancies have not been adequately studied.

Supply

Tablets, 60 mg.

Dosage

The dosage is 60 mg daily. Risedronate (Actonel)

Action

Bisphosphonate that inhibits osteoclast activity and bone resorption but does not interfere with bone mineralization.

Selected Indications Paget's disease of bone.

Metabolism

Risedronate is poorly absorbed by the gastrointestinal tract, especially when taken with food. Fasting absorption is less than 1%. Calcium-, aluminum-, and magnesium-containing supplements and antacids interfere with absorption. Absorbed drug is tropic for bone and will persist within the bony skeleton for years. Excretion is in the urine.

Adverse Reactions

Gastrointestinal intolerances are the most common adverse effects and include diarrhea, nausea, abdominal pain, and esophagitis. About a third of patients may experience arthralgias. Adequate calcium repletion before the initiation of therapy may reduce the risk for musculoskeletal discomfort.

Caution

Risedronate must be taken on an empty stomach, while upright, at least one-half hour before eating. Risedronate is contraindicated in women of childbearing potential.

Supply

Tablets, 30 mg. Dosage

The dosage is 30 mg daily. For Paget's disease, reassessment is indicated after 2 months of therapy. Tiludronate (Skelid)

Action

Bisphosphonate that inhibits osteoclast activity and bone resorption but does not interfere with bone mineralization.

Selected Indications Paget's disease of bone.

Metabolism

Tiludronate is poorly absorbed by the gastrointestinal tract, especially when taken with food. Calcium-, aluminum-, and magnesium-containing supplements and antacids interfere with absorption. Absorbed drug is tropic for bone and will persist within the bony skeleton for years. The drug is not metabolized and is excreted in the urine.

Adverse Reactions

Gastrointestinal intolerances are the most common adverse effects and include diarrhea, nausea, and abdominal pain, but esophagitis and esophageal ulcerations have not been reported.

Caution

Tiludronate must be taken on an empty stomach, while upright, at least 2 hours before eating. Tiludronate is contraindicated in women of childbearing potential. Supply

Tablets, 200 mg. Dosage

The dosage is 400 mg daily. For Paget's disease, reassessment is indicated after 3 months of therapy.

Was this article helpful?

0 0
Lower Your Cholesterol In Just 33 Days

Lower Your Cholesterol In Just 33 Days

Discover secrets, myths, truths, lies and strategies for dealing effectively with cholesterol, now and forever! Uncover techniques, remedies and alternative for lowering your cholesterol quickly and significantly in just ONE MONTH! Find insights into the screenings, meanings and numbers involved in lowering cholesterol and the implications, consideration it has for your lifestyle and future!

Get My Free Ebook


Responses

  • clark
    Does magnesium interfere with raloxifene?
    8 years ago
  • holman
    Is evista ok with a 75 year old with rheumatoid arthritis?
    27 days ago

Post a comment